ABOS
Price
$1.09
Change
+$0.07 (+6.86%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
59.49M
26 days until earnings call
LXRX
Price
$0.70
Change
+$0.03 (+4.48%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
231.53M
7 days until earnings call
Ad is loading...

ABOS vs LXRX

Header iconABOS vs LXRX Comparison
Open Charts ABOS vs LXRXBanner chart's image
Acumen Pharmaceuticals
Price$1.09
Change+$0.07 (+6.86%)
Volume$8.04K
Capitalization59.49M
Lexicon Pharmaceuticals
Price$0.70
Change+$0.03 (+4.48%)
Volume$76.37K
Capitalization231.53M
ABOS vs LXRX Comparison Chart
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. LXRX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and LXRX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ABOS: $1.02 vs. LXRX: $0.67)
Brand notoriety: ABOS and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 149% vs. LXRX: 40%
Market capitalization -- ABOS: $59.49M vs. LXRX: $231.53M
ABOS [@Biotechnology] is valued at $59.49M. LXRX’s [@Biotechnology] market capitalization is $231.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 5 TA indicator(s) are bullish while LXRX’s TA Score has 6 bullish TA indicator(s).

  • ABOS’s TA Score: 5 bullish, 2 bearish.
  • LXRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than LXRX.

Price Growth

ABOS (@Biotechnology) experienced а +4.08% price change this week, while LXRX (@Biotechnology) price change was +34.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

ABOS is expected to report earnings on Aug 18, 2025.

LXRX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($232M) has a higher market cap than ABOS($59.5M). LXRX YTD gains are higher at: -9.032 vs. ABOS (-40.698). ABOS has higher annual earnings (EBITDA): -77.89M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. ABOS (200M). ABOS has less debt than LXRX: ABOS (28.5M) vs LXRX (108M). LXRX has higher revenues than ABOS: LXRX (31.1M) vs ABOS (0).
ABOSLXRXABOS / LXRX
Capitalization59.5M232M26%
EBITDA-77.89M-184.29M42%
Gain YTD-40.698-9.032451%
P/E RatioN/AN/A-
Revenue031.1M-
Total Cash200M238M84%
Total Debt28.5M108M26%
FUNDAMENTALS RATINGS
LXRX: Fundamental Ratings
LXRX
OUTLOOK RATING
1..100
33
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
44
P/E GROWTH RATING
1..100
16
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSLXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MIST1.160.10
+9.43%
Milestone Pharmaceuticals
GSBD10.670.15
+1.43%
Goldman Sachs BDC
BLK892.545.32
+0.60%
Blackrock
LSTR138.150.77
+0.56%
Landstar System
ANIK14.09-0.11
-0.77%
Anika Therapeutics

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with ATOS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then ATOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+3.86%
ATOS - ABOS
54%
Loosely correlated
+11.25%
FHTX - ABOS
50%
Loosely correlated
+10.38%
BEAM - ABOS
48%
Loosely correlated
+3.87%
GBIO - ABOS
48%
Loosely correlated
+9.99%
CRBU - ABOS
47%
Loosely correlated
+0.79%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+5.38%
PLRX - LXRX
42%
Loosely correlated
+2.33%
ABOS - LXRX
38%
Loosely correlated
+3.86%
VCYT - LXRX
37%
Loosely correlated
+1.08%
OCUL - LXRX
36%
Loosely correlated
-0.76%
RXRX - LXRX
36%
Loosely correlated
-0.89%
More